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Inflammation of the human vasculature is a manifestation of many different diseases
ranging from systemic autoimmune diseases to chronic inflammatory diseases, in which
multiple types of immune cells are involved. For both autoimmune diseases and chronic
inflammatory diseases several observations support a key role for T lymphocytes in these
disease pathologies, but the underlying mechanisms are poorly understood. Previous stud-
ies in several autoimmune diseases have demonstrated a significant role for a specific
subset of CD4+ T cells termed effector memoryT (TEM) cells. This expanded population of
TEM cells may contribute to tissue injury and disease progression. These cells exert mul-
tiple pro-inflammatory functions through the release of effector cytokines. Many of these
cytokines have been detected in the inflammatory lesions and participate in the vasculitic
reaction, contributing to recruitment of macrophages, neutrophils, dendritic cells, natural
killer cells, B cells, and T cells. In addition, functional impairment of regulatoryT cells para-
lyzes anti-inflammatory effects in vasculitic disorders. Interestingly, activation of TEM cells
is uniquely dependent on the voltage-gated potassium Kv1.3 channel providing an anchor
for specific drug targeting. In this review, we focus on the CD4+ T cells in the context
of vascular inflammation and describe the evidence supporting the role of different T cell
subsets in vascular inflammation. Selective targeting of pathogenicTEM cells might enable
a more tailored therapeutic approach that avoids unwanted adverse side effects of gen-
eralized immunosuppression by modulating the effector functions of T cell responses to
inhibit the development of vascular inflammation.
Keywords: vascular inflammation, ANCA-associated vasculitis, atherosclerosis, T lymphocytes, effector memory
T cells, Kv1.3 channels
INTRODUCTION
Vasculitides comprises a group of rare diseases, characterized by
inflammation of the blood vessel walls. The clinical manifestations
are dependent upon the localization, the type of vessel involved as
well as the nature of the inflammatory process. Vasculitis con-
stitutes, in most cases, as a primary autoimmune disorder, but
can also be secondary to other conditions. The underlying con-
ditions to secondary vasculitis are infectious diseases, connective
tissue disorders, or hypersensitivity disorders. In general, primary
vasculitides are systemic diseases with variable clinical manifesta-
tions making it difficult to classify. According to the latest Chapel
Hill Consensus Conference, primary systemic vasculitides can be
divided into seven main entities of which three are most common;
large vessel vasculitis, medium vessel vasculitis (MVV), and small
vessel vasculitis (SVV) (1). The group of large vessel vasculitides
(LVV) affects the aorta and its major branches. The two major vari-
ants of LVV are giant cell arteritis (GCA) and Takayasu’s arteritis
(TA). MVV is vasculitis that predominantly affects medium arter-
ies defined as the main visceral arteries and their branches. The
two major categories are polyarteritis nodosa (PAN) and Kawasaki
disease (KD). SVV is divided into anti-neutrophil cytoplasmic
antibody (ANCA)-associated vasculitis (AAV) and immune com-
plex SVV (2). AAV is characterized by necrotizing vasculitis with
few or no immune deposits that predominantly affects small
vessels, which lead to systemic organ damage. AAV are associ-
ated with the presence of circulating ANCA that are directed
against proteinase-3 (PR3) or myeloperoxidase (MPO), proteins
in the cytoplasmic granules of neutrophils. This group of sys-
temic vasculitis includes granulomatosis with polyangiitis (GPA),
primarily associated with antibodies to PR3–ANCA and micro-
scopic polyangiitis (MPA) and eosinophilic granulomatosis with
polyangiitis (EGPA), both principally associated with antibodies
to MPO–ANCA.
Besides autoimmune disorders related to vascular inflamma-
tion, a more common chronic vascular inflammatory disease is
atherosclerosis. Clinical evidence indicates that patients suffering
from large and medium-sized vessel vasculitis show accelerated
atherosclerosis (3). In SVV, this relation is less well defined. How-
ever, many patients with SVV carry several risk factors (e.g.,
impaired renal function, persistent proteinuria, and increased level
of C-reactive protein) that contribute to the acceleration of the
atherosclerotic process (3, 4). Enhanced oxidation processes, per-
sistently activated T cells and reduced numbers of regulatory T
(TREG) cells are among the many pathophysiological factors that
play a role in the acceleration of atherogenesis (5). Both vasculitis
and atherosclerosis, although in nature different forms of chronic
conditions, reveal similarities in T cell repertoire that occur within
the process of vascular inflammation.
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This review provides an overview of the role of adaptive
immune mechanisms in vascular inflammation focusing on the
T lymphocytes in particular. The main emphasis will be on the
role of effector memory T (TEM) cells in vasculitis (i.e., AAV and
atherosclerosis) and the potential therapeutic interventions for
modulating the activity of these cells.
T LYMPHOCYTES: KEY PARTICIPANTS IN VASCULAR
INFLAMMATION
T cells are recruited to the vessel wall in conjunction with
macrophages, but in lesser quantity. In the blood vessel wall or
tissues, T cell responses are initiated by signals generated via the
association of TCR complexes with specific peptide–MHC protein
complexes on the surface of antigen-presenting cells (APCs) and
through signals provided by co-stimulators expressed on APCs.
The responses to antigen and co-stimulators include synthesis of
pro-inflammatory mediators (e.g., IFN-γ) cellular proliferation,
differentiation into effector and memory cells, and performance of
effector functions. These initial events further amplify the inflam-
matory response, aggravating disease progression. Different T cell
subsets exist that can influence vascular inflammation in vari-
ous ways. In the last decade, substantial progress has been made
in the characterization of T cell mediated responses in vascular
inflammation.
T CELL INVOLVEMENT IN AAV AND ATHEROSCLEROSIS
In AAV it has been postulated that ANCA in vivo bind to surface
expressed auto-antigens (PR3 or MPO) on primed neutrophils,
which subsequently activates the neutrophils (6). These activated
neutrophils enhance neutrophil degranulation and the release of
cytotoxic products that promote endothelial cells damage leading
to vascular inflammation and injury (6). This initial inflamma-
tory response mediated by the innate immune system creates a
pro-inflammatory (micro)environment to attract cells from the
adaptive immune system. In the case of autoimmune mediated
vascular pathologies, like AAV, loss of self-tolerance, and contin-
uous antigen presentation also contributes to the involvement of
the adaptive immune system. The contribution of T cell medi-
ated immune responses in vascular inflammation is most likely
because infiltrating T cells are detected in inflammatory lesions
observed in the microvascular bed of kidney, lung, and in nasal
biopsies from AAV patients (7–11). In accordance with these
findings, soluble T cell activation markers [soluble interleukin-
2-receptor (sIL-2R) and soluble CD30] are elevated in plasma or
serum and have been shown to be associated with disease activity
in AAV (12–15). Also, ANCA antigen specific T cells have been
detected in AAV (16, 17). Moreover, the IgG subclass distribution
of ANCA, predominantly consisting of IgG1 and IgG4 implies
isotype switching of ANCA for which T cells are required (18).
Importantly, Ruth et al. demonstrated a pivotal role of T cells in the
expression of crescentic glomerulonephritis (19). They induced
experimental anti-MPO-associated crescentic glomerulonephri-
tis by immunizing C57BL/6 mice with human MPO followed by
subsequent challenge with anti-glomerular basement membrane
(anti-GBM) antibodies. Mice depleted of T cells at the time of
administration of anti-GBM antibodies developed significantly
less glomerular crescent formation and displayed less cell influx in
glomeruli compared with control mice. Interestingly, specific T cell
depleting therapies with anti-CD52 antibodies (Alemtuzumab) or
anti-thymocyte globulin can induce remission in refractory AAV
patients (20, 21).
Atherosclerosis is considered a chronic inflammatory disease,
characterized by a slowly progressing passive lipid accumulation
in large and medium-sized blood vessels that ultimately leads to
the formation of plaques. Both innate and adaptive immunity are
involved in this process. Ait-Oufella et al. recently reviewed the role
of the adaptive immune response in atherosclerosis and discussed
the role of dendritic cells (DCs) in the control of T cell involvement
in atherosclerosis (5). Classically, DCs accumulate in the athero-
sclerotic plaque through direct chemokine mediated recruitment.
DCs take up (atherosclerotic-specific) antigens such as ApoB100
and LDL and become activated and mature. Subsequently, DCs
migrate to draining lymph nodes, where they can present antigens
to naïve T cells. After activation, these T cells develop into effector
cells, clonally expand and enter the bloodstream. When effector T
cells are recruited into atherosclerotic plaques they are reactivated
by antigens presented by local macrophages and DCs, boosting the
immune response. In human atherosclerotic lesions, the ratio of
macrophages to T cell has been reported to be approximately 10:1,
thus T cells are not as abundant as macrophages. However, because
T cells are activated in the lesions resulting in the production
of pro-atherogenic mediators, they can importantly contribute to
lesion growth and disease aggravation. The first evidence of T
cell involvement in atherosclerosis came with the demonstration
that MHC class II positive cells and T cell cytokines (e.g., IFN-
γ) are expressed in human atherosclerotic plaques (22). Later,
the presence of T cells was observed in atherosclerotic plaques
in humans (23, 24) and mice (25, 26). These observations only
demonstrated the association of T cell with atherosclerosis but did
not revealed the role of T cells in atherogenesis. However, Zhou
et al. demonstrated a specific role of T cells in atherogenesis using
an animal model of atherosclerosis. They showed that transfer of
CD4+ T cells into ApoE−/− mice crossed with immunodeficient
mice (scid/scid mice) fully reversed the atheroprotection provided
by T and B cell deficiency (27).
Taken together, these observations indicate that T cell medi-
ated immunity is an important contributor to the pathogenesis
of vascular diseases such as AAV and atherosclerosis. In line with
this, different T cell populations have been identified in vascular
inflammation as will be discussed below. Figure 1 presents a pro-
posed mechanism of the T cell mediated vascular inflammatory
process.
T HELPER CELLS IN VASCULAR INFLAMMATION
Aberrant T helper (TH) cell polarization has been described in
patients with vascular diseases. The involvement of different TH
cells subsets in the pathogenesis of vascular disease has been sug-
gested to depend on disease activity/stage and whether the disease
is localized or systemic.
In AAV, analysis of patients sera for soluble markers associated
with either TH1 cells (IFN-γ, sCD26) or TH2 cells (IL-4, IL-5,
IL-10, IL-13, sCD23, and sCD30) revealed a shift toward a TH2-
type response in patients with active generalized disease, whereas
a TH1-type response is predominant in patients with localized
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FIGURE 1 | Proposed pathophysiological mechanism ofT cell mediated
vascular inflammation. Vascular inflammation is initiated by a
pro-inflammatory trigger such as an infection. Release of pro-inflammatory
cytokines causes priming of neutrophils, up-regulation of adhesion
molecules on endothelial cells, and an expansion of circulation effector T
cells. Activation of primed neutrophils enhances vessel wall adherence and
the transmigration capacity of the neutrophils. Production of reactive oxygen
species and degranulation of fully activated primed neutrophils causes
damage to vascular endothelial cells. This acute injury together with
pro-inflammatory triggers elicits an innate inflammatory response that
recruits T lymphocytes, which replace the neutrophils and either resolves or
mediate the development of vasculitis. In this pro-inflammatory
environment, the innate immune system with antigen-presenting cells
(APCs) and T cells start to mediate the inflammatory response. Distinct
cytokine patterns in combination with a defect in regulatory T (TREG) cell
function or frequency results in expansion of effector memory T (TEM) cells.
The dysbalance in the homeostasis of TREG cells and TEM cells, results in
additional releases of pro-inflammatory cytokines promoting neutrophil
priming and persistent activation of TEM cells. Expanded circulating TEM cells
upregulate their killer immunoglobulin-like receptor (NKG2D) and interact
with their ligand major histocompatibility complex class-I chain-related
molecule A (MICA) on vascular endothelial cells. This event results in the
migration of TEM cells into target tissues, drive granuloma formation leading
to tissues destruction in a perforin-dependent, and granzyme-dependent
way, ending up in vasculitis. The T cell driven vascular inflammatory
response is a multistep process and has different therapeutic possibilities.
For this purpose, selective TEM cell modulation might be beneficial to
regulate the TEM cell activity, proliferation, and migration. Other therapeutic
options are modulation of T cell activation by interfering with co-stimulatory
molecules, depletion of T cells, inhibition of T cell migration, or neutralizing
secreted pro-inflammatory cytokines (This figure was created using Visi
ScienceSlides® Software).
disease (28, 29). Consistent with these observations, analysis of
nasal granulomatous lesions from AAV patients demonstrated a
relative increase of cells expressing TH1-associated markers such
as IFN-γ and CD26 during localized disease, whereas the TH2-
associated marker IL-4 was found in generalized AAV (11). In
addition, Lamprecht et al. compared chemokine receptors on
peripheral blood-derived T cells. The inducible inflammatory
TH1-type chemokine receptor CCR5 was more prominent in the
granulomatous lesions of AAV patients (30).
Similar to AAV, a study on cytokine expression in advanced
human atherosclerotic plaques confirmed the dominance of pro-
inflammatory TH1 cytokines (IFN-γ, TNF-α, and IL-2) (31).
Genetic deficiency in IFN-γ or its receptor in ApoE−/− mice
reduced atherosclerotic lesion formation and enhanced plaque
stability (32), whereas exogenously administered IFN-γ enhanced
atherosclerosis in ApoE−/− mice (33). Intriguingly, it seems that
the protective effect of IFN-γ deficiency is restricted to male
ApoE−/− mice (34). In addition, several studies revealed that
intervention in IL-12 or IL-18 gene, or receptor function was
found to reduce plaque development in mouse models of athero-
sclerosis (35–37). Furthermore, administration of these cytokines
accelerated disease progression (38, 39). Collectively, these data
point toward a pro-inflammatory TH1 response in atherosclerosis.
However, the role of TH2 immune responses in atherosclerosis is
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controversial. IL-4, the signature cytokine of the TH2 lineage, is not
frequently observed in human atherosclerotic plaques (31). More-
over, experimental studies examining the involvement of TH2 cells
are contradictory, some showing pro-atherosclerotic effects (36,
40), whereas others show no or athero-protective effects (41, 42).
Overall, the balance between TH1 and TH2 cells plays a key role
in the development of vascular inflammation. Interestingly, in the
last decade TH17 cells have emerged as a new CD4+ T cell subset
characterized by secretion of IL-17A and other cytokines includ-
ing IL-17F, IL-21, and IL-22. These cells are considered another
major pathogenic effector subset involved in the development of
inflammatory and autoimmune diseases (43).
IL-17 has been reported to promote the release of the pro-
inflammatory cytokines IL-1β and TNF-α from macrophages (44),
which are essential for priming and activation of neutrophils. Fur-
thermore, this pro-inflammatory milieu induces CXC chemokine
release (45) and up-regulation of endothelial adhesion mole-
cules (46) responsible for the recruitment of neutrophils to the
site of inflammation (47). These pro-inflammatory events sug-
gest that IL-17 may directly contribute to the acute vascular
inflammatory response in AAV. Convincing experimental evidence
that support this notion comes from several studies. Hoshino
et al. demonstrated that neutrophils produce IL-17A and IL-23
in response to MPO–ANCA creating local conditions to pro-
mote TH17-mediated autoimmunity (48). In addition, Gan et al.
showed that immunization of C57BL/6 mice with murine MPO
resulted in MPO-specific dermal delayed type hypersensitivity and
systemic IL-17A production (49). Upon injection of low-dose
anti-GBM antibodies these mice developed glomerulonephritis. In
contrast, IL-17A deficient mice were nearly completely protected
from disease induction due to reduced neutrophil recruitment
and MPO deposition (49). Consistent with this finding, Odobasic
et al. demonstrated that IL-17A contributes to early glomerular
injury, but it paradoxically, attenuates the severity of fully estab-
lished crescentic disease by limiting the TH1 responses (50). They
used a mouse model of crescentic anti-GBM glomerulonephritis
assessing the renal injury and immune responses in IL-17A−/−
and in wild-type (WT) mice. Crescentic glomerulonephritis was
enhanced in IL-17A−/− mice, with increased glomerular T cell
accumulation and augmented TH1 responses (50). In contrast,
mice lacking IL-12(p35), the key TH1-promoting cytokine, had
decreased TH1 responses and increased TH17 responses and devel-
oped less severe crescentic glomerulonephritis than WT animals
(50). Thus, they provided evidence that TH1 responses mediate
severe crescentic injury and that TH1 and TH17 cells counter reg-
ulate each other during disease development in this model. In
line with the in vivo observation, our group observed a skew-
ing toward TH17 cells following in vitro stimulation of peripheral
blood samples of AAV patients (51). Moreover, it has been shown
that CD4+CD45RClow cells (T cells with a memory phenotype) are
a source of IL-17 in AAV patients (52). These observations were
corroborated by Nogueira et al., demonstrating significant ele-
vated levels of serum IL-17A and its associated upstream cytokine
IL-23 in acute AAV patients (53). Additionally, auto-antigen-
specific IL-17 producing cells were significantly elevated in patients
during disease convalescence compared to healthy controls (53).
Moreover, increased frequencies of circulating TH17 cells have
been observed in various forms of vasculitis (GCA, EGPA, and
Behçet disease) and correlated with disease activity (54–58).
A possible explanation for the involvement of TH17 cells in
AAV lies within the major physiological role of TH17 cells. Physio-
logically, TH17 cells are important in the defense against fungi and
bacterial infections [e.g., Staphylococcus aureus (S.aureus) infec-
tions] by activating neutrophils through the production of IL-17
and IL-17F. It has been shown that peptidoglycans and superanti-
gens of S. aureus might have an immunomodulatory effect on DCs
by imprinting of a strong TH17 polarization capacity (59). Fur-
thermore, S. aureus α-toxin was shown to induce IL-17A secretion
in CD4+ T cells (60). In addition, Zielinski et al. demonstrated that
S. aureus specific TH17 cells produced IL-17 and surprisingly could
produce IL-10 upon restimulation (61). Intriguingly, chronic nasal
carriage of S. aureus has been found to be an important risk factor
for disease relapse in AAV patients (62). This suggests that carriage
of S. aureus may drive the TH17 responses in AAV.
The role of TH17 cells in atherosclerosis remains controversial.
It has been demonstrated that TH17 cells and IL-17 accumu-
late in atherosclerotic lesion of both mice and humans, but both
atherogenic as well as athero-protective effects of IL-17 have been
reported (63–67). Studies in ApoE−/− mice genetically deficient
for IL-17 or treated with anti-IL-17A antibodies demonstrated
that absence or depletion of IL-17 attenuated development of ath-
erosclerosis (65, 68). Also, Ldlr−/− mice transplanted with bone
marrow from mice deficient in IL-17 receptor showed smaller ath-
erosclerotic lesions (63). In patients, IL-17A expressing T cells were
detected in atherosclerotic lesions and increased IL-17 expression
in these lesions has been shown to be associated with increased
inflammation and plaque vulnerability (67). In contrast to the
pathogenic role of TH17 cells, Taleb et al. found a protective role
for TH17 cells in atherosclerosis. Using Ldlr−/− mice deficient for
suppressor of cytokine signaling 3 (SOCS3), a suppressor of sig-
naling from IL-17, showed less disease development (64). In the
same study, administration of an anti-IL-17A antibody accelerated
atherosclerosis, indicating a protective role for TH17 cells (64).
A possible explanation for these contradictory observations
may be that IL-17 is not only produced by T cells. The pres-
ence of different IL-17 isoforms (IL-17A, -E, and -F) in human
atherosclerotic plaques revealed that the IL-17 family cytokines
were expressed by various cells of the immune system (e.g., neu-
trophils) depending on the stage of the atherosclerotic plaque (66).
Furthermore, not only immune cell are targets of IL-17. It has been
demonstrated that endothelial cells and smooth muscle cells are
likely to be IL-17E-responsive, given the expression of IL-17 recep-
tor components on these cells and transient activation of ERK1/2
upon stimulation with recombinant IL-17E (66). Thus, this indi-
cates a complex contribution of IL-17 in atherogenesis depending
on the isoform and phases of atherosclerosis.
Beside IL-17, TH17 cells can also produce IL-21, a cytokine
that is produced primarily by T follicular helper (TFH) cells. IL-
21 is required for B cell class switching, antibody production
(69), and induces differentiation of B cells toward plasma cells
by synergizing with B cell activating factor (BAFF) (70, 71). The
role of IL-21 has been demonstrated in Behçet disease, a form
of variable vessel vasculitis. Geri et al. demonstrated increased
serum levels of IL-21 that correlated with the disease activity in
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patient with Behçet disease (58). In addition, they showed that
IL-21 producing central memory CD4+ T cells positively corre-
lated with TH17 responses and negatively correlated with FoxP3
TREG cells. Conversely, blockade of IL-21 with IL-21R-Fc fusion
protein resorted the balance between TREG cells and TH17 cells
by suppressing IL-17A production and increasing FoxP3 expres-
sion by CD4+ T cells (58). Interestingly, a significant increased
population of IL-21 producing TFH cells was observed in the cir-
culation of AAV patients (72). In addition, IL-21 was shown to
enhance the production of cytotoxic products such as granzyme B
and perforin, by CD8+ T cells and natural killer (NK) cells (73).
Based on the studies in various forms of vasculitis it is therefore
conceivable that IL-21 together with IL-17 plays a critical role in
the pathogenesis of AAV.
In atherosclerosis, no major studies have been conducted to
date to investigate the role of TFH cells, but IL-21 may be involved
in tissue damage. There is evidence that IL-21 acts directly on gut
epithelial cells to induce the production of macrophage inflam-
matory protein-3α (MIP-3α), a chemokine that attracts both TH1
and TH17 cells to inflamed tissues (74). Given that endothelial cells
are known to produce MIP-3α, it is possible that IL-21 enhances
the migration and accumulation of TH1 and TH17 cells into the
vascular wall in both vasculitis and atherosclerosis resulting in
inflammation.
REGULATORY T CELLS IN VASCULAR INFLAMMATION
The actions of TH cells can be balanced by TREG cells, a sub-
population that is characterized by their ability to suppress a
variety of physiological and pathological immune responses and
prevent autoimmunity (75). TREG cells are characterized by their
expression of forkhead/winged helix transcription factor (FoxP3)
that is required for their development and function (76). Defects
in TREG function or reduced numbers of TREG cells have been
described in several autoimmune disorders and chronic inflamma-
tory disorders associated with vascular inflammation (77). To date
different research groups reported controversial results regarding
the frequency of TREG cells in AAV patients compared to healthy
controls. However, a consistent finding has been that these stud-
ies all reported impaired functionality of circulating TREG cells
(78–80). It has been found that the suppressive function of TREG
cells was defective in GPA patients compared to healthy controls
(78). However, the GPA patients showed a significant increase of
memory FoxP3+CD25high TREG cells. Consistent with this find-
ing, Klapa et al. demonstrated an increased number of FoxP3+ T
cells as well as phenotypical and functional alteration of TREG cells
in GPA patients (79). They reported an increased number of inter-
feron receptor I-positive TREG cells in the peripheral blood of GPA
patients. In addition, they showed that IFN-α exaggerates func-
tional TREG impairment ex vivo in response to the auto-antigen
PR3 (79). Furthermore, Morgan et al. also reported altered TREG
function in GPA patients (80). They observed that TREG cells from
healthy controls and from ANCA-negative patients were able to
suppress T cell proliferation to PR3, whereas TREG cells from PR3-
ANCA-positive patients failed to suppress this antigen specific
response (80). Dysfunction of TREG cells is thus believed to play
a role in the development of GPA. In contrast, TREG function in
MPA patients was comparable to that in healthy controls although
FoxP3 levels were diminished, suggesting that in MPA a numer-
ical deficiency of TREG cells exists (81). Additionally, Saito et al.
demonstrated that the proportion of TREG cells in the peripheral
blood reflects the relapse or remission status of EGPA patients.
They observed that FoxP3-expressing cells and IL-10 producing
TREG cells were detected in lower frequencies in patients with a
relapse compared to patient in remission (82). However, the sup-
pressive function of TREG cells in EGPA patients still needs to
be investigated. All together there are some inconsistent observa-
tions regarding the number and/or frequencies of TREG cells in
AAV patients. These differences might be due to variations in the
methodology and gating strategies for the TREG cells between the
different studies. However, in all studies impaired functionality of
the TREG subset has been demonstrated indicating that TREG cells
from AAV patients are not able to suppress proliferation of other
TH cell subsets.
The terminally differentiated TREG cells are not defined entirely
by FoxP3 expression, and the FoxP3+ T cell population is het-
erogeneous, consisting of a committed TREG lineage and an
uncommitted subpopulation with developmental plasticity (83).
It has been reported that human TREG cells can convert into pro-
inflammatory IL-17 producing T cells depending on a specific
cytokine environment (81–83). Both TH cell subsets (i.e. TREG
and TH17 cells) may develop from the same precursors under
distinct cytokine conditions, and a subset of IL-17-producing
CD4+FoxP3+ TREG cells can be generated upon polarization
by pro-inflammatory cytokines such as IL-6, which is crucial in
orchestrating the balance of TREG and TH17 cells (84–86). It has
been shown that the combination of transforming growth factor-
beta (TGF-β) and IL-6 treatment can synergistically promote
FoxP3 degradation (87), and induce the transcription of ROR-
γt, which in turn participates in the induction of IL-17 expression
and mediates the skewing toward a TH17 cell phenotype.
Besides the local cytokine environment that orchestrates the
balance of TREG and TH17 cells, the functional stability of FoxP3
might influence the developmental pathway. Post-translational
modifications can transiently alter the functionality of transcrip-
tion factors, and there is evidence that FoxP3 can be regulated
via acetylation. For example, hyperacetylation of FoxP3 increases
the stability of FoxP3 and treatment with histone deacetylases
inhibitors results in increased numbers and functional TREG cells
(88). Indeed, Koenen et al. demonstrated that histone deacetylases
inhibitors suppresses the conversion from TREG to TH17 cells (89).
In addition, different isoforms of FoxP3 have been investigated
in human TREG that have been shown to affect TREG function
and lineage commitment. More specifically, the full length iso-
form FoxP3 interacts with ROR-γt and inhibits the expression
of genes that define the TH17 lineage, whereas the isoform lack-
ing exon 2, FoxP3∆2 fails to inhibit ROR-γt. Upon stimulation
in an inflammatory environment these non-functional TREG con-
vert into IL-17 producing effector T cells. Based on these findings,
our previous described non-functional TREG cells in AAV patients
may lack their suppressive function due to the up-regulation of
FoxP3∆2 that fails to inhibit ROR-γt mediated IL-17 transcrip-
tion. Indeed, Free et al., demonstrated that TREG cells from patients
with active AAV disproportionately used FoxP3∆2, which might
alter TREG cell function (90).
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In atherosclerosis, several studies have demonstrated a pro-
tective effect of TREG cells. FoxP3+ T cells have been found
in atherosclerotic plaques of humans, although in low numbers
(91). In mice, the TREG cytokine products IL-10 and TGF-β, have
been demonstrated to induce potent anti-atherosclerotic activities.
Genetic inactivation or blockade of IL-10 and TGF-β with neu-
tralizing antibodies aggravated atherosclerosis in mice (92, 93).
Depletion of TREG cells directly addressed the protective role of
these cells in atherosclerosis. Significant aggravation of atheroscle-
rosis was observed in Ldlr−/− mice with reduced TREG cell num-
bers, achieved either by deletion of CD80/86 or CD28, inducible
T cell co-stimulators, or upon treatment with CD25-depleting
antibodies (94, 95).
Thus, the interplay and imbalances between different TH cells
are important in the pathogenesis of vascular inflammatory dis-
eases (Table 1). An imbalance in TH1/TH2 toward the TH1
response promotes the development of vascular inflammation,
whereas skewing toward prominent TH2 and TREG responses is
anti-inflammatory and results in a reduction of vascular inflam-
mation. In AAV, TH17 cells are considered to be pathogenic but
how TH17 cell affect inflammation in atherosclerosis still needs to
be determined.
INVOLVEMENT OF CD4+ T EFFECTOR MEMORY CELLS
As mentioned above, several observations support the involve-
ment of CD4+ TH cells in the pathogenesis of vascular inflam-
matory diseases like AAV and atherosclerosis. In line with these
observations, an expanded population of CD4+ T cells lacking the
co-stimulatory molecule CD28 was observed in peripheral blood
and in inflammatory lesions of AAV patients (10, 96). Further-
more, these CD4+CD28− T cells are a major source of IFN-γ and
TNF-α, display up-regulation of the T cell differentiation marker
CD57 and show cytoplasmic perforin expression, indicating the
cytotoxic potential of these cells (10).
Consistent with these findings, our group observed a signifi-
cant increase in the frequency of circulating CD4+ TEM cells in
the peripheral blood of AAV patients in remission (97). Subse-
quently, it was found that the number of these circulating CD4+
TEM cells decrease during active disease when compared with the
number during complete remission (97). We proposed that these
CD4+ TEM cells migrate toward inflamed tissues (97). In accor-
dance, infiltrating T cells found in granulomas within lung and/or
kidney tissues resemble mainly the CD4+ T cell memory phe-
notype. A remarkable increase in CD4+ TEM cells in the urinary
sediment with a concomitant decrease of circulating CD4+ TEM
cells in patients with active renal involvement strongly suggests
migration of CD4+ TEM cells during active renal disease into the
affected organs (98). This finding might reflect the role of CD4+
TEM cells in renal injury during active disease. In line with these
findings, is the observation that CD4+ TEM cells expressing CD134
are expanded in peripheral blood of AAV patients (99). It has been
reported that the ligand for CD134 (CD134L) is expressed on
endothelial cells (100) and ligation of CD134 contributes to T
cell migration and tissue infiltration through its interaction with
Table 1 |T cell subsets associated with vascular pathologies.
T cell subset Key characteristic Finding in vascular pathology Reference
TH1 cell Production of IFNy Skewing toward TH1 in localized GPA (11, 28–30)
Enhances cellular immune responses Dominant TH1 cytokine prolife in human atherosclerotic plaques (31)
TH2 cell Production of IL-4 Skewing toward TH2 in active generalized GPA, and in EGPA (28, 29)
Promote humoral immune response
TH17 cell Production of IL-17 Skewing toward TH17 in GPA during quiescent disease, and in EGPA
and Behçet disease during active disease
(51, 57, 58)
Defense against fungi and bacterial infections
Mediates pathogenic responses in autoimmune
diseases
Increased frequencies of TH17 cells in GCA (54–56)
Contradictory observations of TH17 cell function in atherosclerosis,
IL-17A expressing T cells are present in human atherosclerotic lesions
and associated with increased inflammation and plaque vulnerability.
However, mouse models reveal a protective effect of TH17 cells
(63–67)
TFH cell Production of IL-21 Increased TFH population in GPA (72)
IL-21 required for B cell class switching TFH cytokine IL-21 correlates with disease activity in Behçet disease (58)
TREG cell Production of IL-10 Contradictory observations regarding the frequency of TREG cells in
GPA patients, however all studies report an impaired function of TREG
cells in GPA
(78–80, 90)
Regulation of other T cell subsets
Maintain peripheral tolerance to self antigens
Numerical defect of TREG cells in MPA (81)
TREG cells reflect relapse and remission status in EGPA (82)
Reduced frequencies of TREG cells in GCA (55, 56)
Low number of TREG cells in human atherosclerotic plaques, mouse
models reveal a protective effect of TREG cells
(91–93)
GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; GCA, giant cell arteritis; MPA, microscopic polyangiitis.
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CD134L on vascular endothelial cells (101). Furthermore, CD134
expressing T cells have been detected in the inflammatory lesions
of AAV patients (99), supporting the hypothesis that CD4+ TEM
migrate to inflamed areas. The fact that CD4+ TEM cells migrate
to the kidney during active disease suggests that a specific stimulus
is being expressed by the (micro)vascular bed of the kidney, which
attracts these cells.
In atherosclerotic disease, analysis of CD4+ T cell subsets (i.e.,
naïve T cells, TCM, and TEM cells) revealed that CD4+ TEM cells are
key players in disease pathogenesis (102). It has been shown that
the frequency of circulating TEM cells was significantly increased
in Ldlr−/− and ApoE−/− mice compared to control C57BL/6 mice
and also correlated with the extent of atherosclerotic lesions (102).
In line with these observations, Almanzar et al. demonstrated
that T cells isolated from early atherosclerotic lesions are mostly
CD4+ TEM cells (24). Subsequently, the intralesional atheroscle-
rotic CD4+ T cells produce high amounts of the pro-inflammatory
cytokines IFN-γ and IL-17 (24), which suggest that memory T cells
in atherosclerotic plaques are in a state of activation reflecting the
pro-inflammatory cytokine production.
At the functional level, CD4+ TEM cells have been shown to
mimic features of NK cell including surface expression of the
NK group 2 member D (NKG2D) and cytotoxic potential (103,
104). NKG2D is an activating C-type lectin-like receptor, which
differs from other NKG2 family members as it apparently lacks
an antagonist and substitutes for CD28-mediated co-stimulatory
signaling in CD28− TEM cells (104). One of the NKG2D ligands
in human is the major histocompatibility complex class-I chain-
related molecule A (MICA). MICA is usually absent on normal
cells, but expressed upon cellular stress on target cells such as
fibroblasts, epithelial cells, and endothelial cells (104). The expres-
sion of MICA on the surface of the endothelium makes this poly-
morphic molecule a potential target in vasculitis. In rheumatoid
arthritis (RA), an other chronic and systemic autoimmune disor-
der, an unusual CD4+CD28−NKG2D+ population was detected
in peripheral blood and synovial tissue (105). Furthermore, the
NKG2D ligand MICA is dramatically upregulated in RA syn-
oviocytes and is capable of activating autoreactive T cells in an
NKG2D-dependent manner (105). In addition, it has been shown
in patients with Crohn’s disease, a chronic inflammatory disor-
der, that CD4+NKG2D+ TEM cells can kill target cells that express
MICA via NKG2D–MICA interaction (106). These findings in
RA and Crohn’s disease translate very well to AAV. In AAV, it has
been found that NKG2D was anomalously expressed on circu-
lating CD4+CD28− TEM cells (107). Furthermore, it has been
demonstrated that NKG2D, MICA, and IL-15 are simultaneously
expressed in granulomatous lesions in AAV patients. Importantly,
it was reported that survival, expansion, and cytotoxic properties
of CD4+NKG2D+ T cells were dependent on IL-15 signaling in
AAV (108). Therefore, it is tempting to speculate that combined
IL-15 and MICA expression contributes to the killing mecha-
nisms of CD4+NKG2D+ T cells in vessel inflammation and disease
progression in AAV.
In atherosclerosis, Xia et al. reported that immune activation
resulting from NKG2D–ligand interaction promotes atheroscle-
rosis (109). They observed soluble MICA in sera and upregu-
lated MICA expression in atherosclerotic plaques of patients with
type 2 diabetes mellitus. Moreover, they investigated the role of
NKG2D in atherosclerosis using ApoE−/− mice genetically defi-
cient for NKG2D or treated with anti-NKG2D antibodies. Prevent-
ing NKG2D–ligand interaction resulted in a dramatic reduction
in plaque formation and suppressed systemic and local inflam-
mation mediated by multiple immune cell types. Since this is the
only study reported on NKG2D in relation with atherosclerosis
development, further studies are needed to fully elucidate the role
of NKG2D in the pathogenesis of atherosclerosis.
T CELL DIRECTED THERAPEUTIC INTERVENTIONS
As described in this review, T cells and T cell migration are piv-
otal in vascular inflammatory diseases such as vasculitides and
atherosclerosis. Therefore interfering with T cell activation, prolif-
eration, and migration might be a beneficial approach to dampen
the inflammatory response and cell-based therapy to modulate the
T cell compartment may be a therapeutic option.
Regulatory T expansion may be of benefit to counterbalance
persistent T cell activation in AAV. In this respect, treatment with
low-dose IL-2 has been found to promote TREG recovery and clin-
ical improvement in patients with autoimmune vasculitis (110).
Interestingly, tocilizumab, a humanized anti-IL-6 receptor anti-
body used in the treatment of RA demonstrated that blocking IL-6
function affects the balance between TH17 and TREG cells favoring
a more anti-inflammatory response (111). In addition, control of
T cell activation might be an attractive therapeutic possibility. In
this regard, blockage of the co-stimulatory pathway CD28/CD80
using CTLA-4 fusion proteins has successfully been used in RA
(112) and shown to be well tolerated in a small open-label trial
in GPA patients (113), which suggests this treatment as a possible
therapeutic opportunity in AAV.
Modulation of other T cell subsets is also considered as a
means for future therapies. For example, since TH17 cells con-
tribute to inflammation and granuloma formation, this TH cell
subset could be a novel therapeutic target for AAV. Depletion of
TH17 cells by targeting specific surface proteins may be difficult
as TH17 cells share many surface markers with other T cell sub-
sets. Another therapeutic approach could be to specifically target
its signature cytokine, IL-17, which would probably be more fea-
sible. Indeed, neutralizing IL-17 by IL-17A specific antibodies or
administration of soluble IL-17 receptors reduces inflammation
in animal models of atherosclerosis (49, 65, 68, 114). Several IL-
17A blockers, including the anti-IL-17A monoclonal antibodies
secukinumab and ixekizumab, and the anti-IL-17 receptor sub-
unit A monoclonal antibody brodalumab have been evaluated in
clinical trials (115–117), and shown to induce clinically relevant
responses in patients. Besides IL-17, IL-21 also seems an inter-
esting target in the treatment of autoimmune mediated vascular
inflammation. Manipulation of IL-21 levels may have desirable
therapeutic consequences as it might reduce the recruitment of
inflammatory TH1 and TH17 cells to inflammatory lesions pre-
venting tissue damage and inhibit expansion of autoreactive B
cells. Recently, phase I clinical trials using an IL-21-specific mono-
clonal antibody have been completed for RA (NCT01208506 and
EudraCT-2011-005376-42, www.clinicaltrial.gov) but terminated
for SLE (NCT01689025, www.clinicaltrial.gov). Neutralization of
IL-17 or IL-21 could therefore represent also novel therapeutic
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approaches for patients with AAV. However, experiments using
animal models of AAV and clinical trials need to elucidate the
therapeutic potential of neutralizing IL-17 and IL-21 in AAV. It is
important to note that interfering with the cytokine environment
might also cause disturbances in the developmental pathways of
the different T cell lineages. Since there is a tight interplay between
different T cell lineages such as the TREG and TH17 cells,one should
be cautious in modulating the cytokine environments. Besides tar-
geting pro-inflammatory cytokines like IL-17 or IL-21, one can
also consider to target effector T cells, which are predominantly
responsible for the production of these cytokines.
EFFECTOR MEMORY CD4+ T CELLS AS THERAPEUTIC TARGETS
According to aforementioned evidence in AAV and atherosclerosis,
CD4+ TEM cells are considered to play a pivotal role in the patho-
genesis of vascular inflammation and therefore, may serve as a
potential therapeutic target. Selective targeting of CD4+ TEM cells
without impairing other parts of the humoral or cellular immune
system could be a major step forward in the treatment of chronic
and/or autoimmune mediated vascular inflammation disorders.
The capacity of CD4+ TEM cells to interact with target cells via
NKG2D–MICA interaction and attack them by releasing cytolytic
enzymes has been demonstrated (104, 106). Therefore, NKG2D
expressed on pathogenic TEM cells could be an interesting target
to inhibit the pathogenic effects of TEM cells. Interestingly, inter-
ference with NKG2D signaling using anti-NKG2D antibodies has
shown beneficial effects when administered early in two differ-
ent mouse models. Blockade of NKG2D prevented autoimmune
diabetes in non-obese diabetic mice (118) and attenuated transfer-
induced colitis in SCID mice (119). However, no clinical trials on
the blockade of NKG2D or its ligands in autoimmune diseases
have been conducted.
Besides interfering with the NKG2D–MICA interaction, bio-
physical analyses revealed that ion channels expressed by immune
cells perform functions vital for cellular homeostasis and T cell
activation [reviewed by Ref. (120)]. In particular, human T cells
express two types of potassium channels (voltage-gate potassium
Kv1.3 channel; Kv1.3 and Ca2+-activated potassium KCa3.1 chan-
nel; KCa3.1) that play a major role in their activation. Interestingly,
Kv1.3 channels and the KCa3.1 channels are expressed on T cells
in a distinct pattern that depends on the state of activation as well
as on the state of differentiation of the given T lymphocyte subset
(121). It has been shown that Kv1.3 channels are highly expressed
in CD4+ TEM cells (~1500 channels per cell), whereas naïve and
TCM cells express lower levels of Kv1.3 channels (~250 channels
per cell) (122). Therefore, Kv1.3 channels may serve as an attrac-
tive target for specific immunomodulation in TEM cell mediated
chronic or autoimmune diseases. Hu et al. have demonstrated
that genetic silencing of Kv1.3 in human CD4+ T cells results in
selective expansion of TCM cells and the disappearance of TEM
cells after multiple rounds of stimulation with anti-CD3/CD28
in vitro, suggesting that Kv1.3 is essential for maintaining the TEM
pool (123). Indeed, selective blocking of Kv1.3 channels inhibits
Ca2+ signaling, pro-inflammatory cytokine production, and pro-
liferation of CD4+ TEM cells in vitro, with little or no effects
on CD4+ naïve and TCM cells (124). Furthermore, it has been
shown that specific Kv1.3 blockade suppressed TEM cell motility
in inflamed tissues, but had no effect on homing to or motil-
ity in lymph nodes of naïve and TCM in vivo (125). In addition,
Kv1.3 blockers ameliorate disease development in animal models
of multiple sclerosis, RA, T1DM, and contact dermatitis without
compromising the protective immune responses to acute infec-
tions (124, 126, 127). Noteworthy, Gocke et al. demonstrated that
genetic deletion of Kv1.3 biases T cells toward an immunoreg-
ulatory phenotype and renders mice resistant to experimental
autoimmune encephalomyelitis (128). They showed that Kv1.3 is
required for expression of pro-inflammatory cytokines IFN-γ and
IL-17, whereas its absence led to increased IL-10 production (128).
Thus, it is tempting to speculate that pharmacological blockade
or genetic suppression of Kv1.3 channels can be employed as a
means to skew CD4+ T cell differentiation toward a regulatory
phenotype, which might be beneficial for autoimmune mediated
vascular diseases in general. Importantly, Kv1.3 blockers have a
good safety prolife in rodents and primates and do not compro-
mise the protective immune response to acute viral (Influenza) or
bacterial (Chlamydia) infections (124, 125, 127).
Taken together, these studies demonstrated that specific block-
ade of Kv1.3 channels on TEM cells suppresses the pathogenicity
of TEM cells by inhibition of their activation, proliferation and
migration. Recently, it has been shown that expression of T cell
Kv1.3 channels correlated with disease activity in ulcerative colitis
(129). Therefore, Kv1.3 channels on CD4+ TEM cells in chronic
or autoimmune inflammatory diseases could constitute a novel
pharmacological target in immunomodulation therapies and at
the same time may serve as a marker for disease activity.
CONCLUSION
Vascular inflammation can be driven by chronic inflammatory
disorders or by autoimmune mediated diseases. In this inflam-
mation process, there is a tight interplay between the innate and
adaptive immune system. However, as described in this review,
substantial evidence point to an important role for cell medi-
ated adaptive immune responses in the pathogenesis of vascular
inflammation. In particular, T cells in chronic or autoimmune
mediated vascular inflammation show several functional abnor-
malities. The T cell compartment shows dysregulation in TH
subsets, including an imbalance between TH1 and TH2 cells, skew-
ing toward TH17 response and defective functions of TREG cells.
However, the importance of TH2 and TH17 cells in atherogene-
sis is controversial. The underlying mechanisms responsible for
orchestrating the aberrations within the T cell compartment are
not completely understood. However, multiple studies indicate
an interplay between TREG cells and TH17 cells. It has been sug-
gested that in the context of an inflammatory environment TREG
cells convert into IL-17 producing cells. Furthermore, TREG cells
clearly have a protective effect in experimental models of athero-
sclerosis. In AAV, TREG cells are often quantitatively or functional
defective. It has been suggested that a defect in TREG cell func-
tion, may also contribute to the expansion of CD4+ TEM cell
population and migration of these cells to inflamed sites. Indeed,
observations in AAV and atherosclerosis support TEM cell involve-
ment in vascular inflammation that in part contributes to tissue
damage. The persistent activation of TEM cells results in a selec-
tive up-regulation of Kv1.3 channels. These potassium channels
Frontiers in Immunology | Inflammation October 2014 | Volume 5 | Article 504 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lintermans et al. T cells in vascular inflammatory diseases
play a key role in TEM cell homeostasis, proliferation, and acti-
vation. Therefore, they seem to be a highly interesting target for
immunomodulation of TEM cells without compromising other
subsets of the T cell compartment.
Currently efforts are being made to develop biological agents
that can modulate the different T cell compartments specifically. In
the case of autoimmune mediated vascular diseases such strategies
could first be used for the prevention of disease flares. Consider-
ing that expansion of TREG cells might be inadequate to control
inflammatory responses, regulating TEM cells would probably be
the most effective approach. This approach may diminish effec-
tor responses and convert these into a more disease regulating
response. To develop such therapeutic strategies further studies
on the basic immunological properties of TEM and TREG cells
in especially humans are needed. Investigation of the functional
characteristics of TEM cells in the pathogenesis of vascular inflam-
matory diseases and selective targeting of these cells will enable
their application for the treatment of TEM cell mediated vascular
diseases.
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